A treatment regimen combining Darzalex Faspro (daratumumab and hyaluronidase-fihj) with three other medications is now approved in the U.S. for all people newly diagnosed…
News
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to QTX-2101, an oral formulation of an approved chemotherapy drug, as a potential treatment…
A first-in-human clinical trial testing RMC-5127, an experimental treatment for people with pancreatic cancer and other cancers marked by a specific genetic mutation called…
The majority of patients with recurrent glioblastoma remain alive following treatment with an experimental immune-modulating combination, according to a clinical trial update from Immunitybio.
Treatment with relacorilant plus standard chemotherapy was shown in a clinical trial to significantly improve survival compared with chemo alone for people with hard-to-treat ovarian…
A clinical trial in Australia that’s testing the genetic therapy KLN-1010 in people with hard-to-treat multiple myeloma has won regulatory approval to add new…
The U.S. Food and Drug Administration (FDA) has granted breakthrough designation to soficabtagene geleucel (sofi-cel), a cell therapy designed to treat relapsed or refractory T-cell…
After a year of treatment with the experimental medication atebimetinib as an add-on to chemotherapy, about two-thirds of pancreatic cancer patients in an ongoing…
Curasight‘s experimental cancer therapy, uTREAT, has successfully reached its target in the brain of the first patient dosed in a Phase 1 clinical trial.
The U.S. Food and Drug Administration (FDA) has granted its breakthrough therapy designation to sofetabart mipitecan as a potential treatment for people with platinum-resistant epithelial…
